Health Sciences Associate Clinical Professor, Department of Clinical Pharmacy Practice
School of Pharmacy & Pharmaceutical Sciences

psychiatry, mental health, student mental health, long acting injectable antipsychotics, antipsychotics

Dr. Farah Khorassani is a psychiatric pharmacist with a passion for improving psychotropic prescribing and pharmacy education. Dr. Khorassani was the education and training consultant for a federal grant awarded by the Substance Abuse and Mental Health Services Administration (SAMHSA), which funded pharmacy student training to screen for substance use. Dr. Khorassani also served as the founding faculty advisor for the student chapter of the college of psychiatric and neurologic pharmacists (CPNP) at St. John's University. An advocate for mental health discussion in all populations, she has also been involved in research exploring anxiety in pharmacy students. Clinically, Dr. Khorassani has worked to address the underutilization of long-acting injectable (LAI) psychotropics, particularly in those with severe mental illness. At Bellevue Hospital, she worked to get multiple LAIs added to the formulary so that these medications could be more accessible to their underserved population. Dr. Khorassani has combined her enthusiasm for teaching and collaborative skills to become involved in multidisciplinary education. Besides classroom and experiential teaching, Dr. Khorassani also enjoys mentoring pharmacy students, residents, and other healthcare providers.

Khorassani F. Battle of the bulge: antipsychotic-induced weight gain. The Carlat Hospital Psychiatry Report (TCPR) 2021;1 (5);1-12.

Khorassani F. Vesicular Monoamine Transporters for Tardive Dyskinesia. The Carlat Hospital Psychiatry Report (TCPR) 2021;1 (3);1-8.

Khorassani F, Espejo G. The impact of pharmacy-driven physician naloxone training on an inpatient psychiatric unit. Ment Health Clin [Internet] 2021;11(2):101.

Khorassani F, Hassani B, Conry J, Espejo, G. Evaluation of anxiety in Doctor of Pharmacy students in their first through fourth professional years. Curr Pharm Teach Learn 2021;13(6):628-34.

Khorassani F, Sousonis F, Lopez L. Risperidone and paliperidone-induced hepatotoxicity: case report and review of literature. Am J Health Syst Pharm 2020; 77(19);1578-84.

Khorassani F, Talreja O. Esketamine: a novel agent for treatment-resistant depression. Am J Health Syst Pharm 2020; 2020;77(17):1382-1388.

Khorassani F, Talreja O, Luther K. Valbenazine and deutetrabenazine: vesicular monoamine transporter 2 inhibitors for tardive dyskinesia. Am J Health Syst Pharm 2020 Jan 24;77(3):167-174.

Ng K, Khorassani F. Options for managing treatment-resistant depression. US Pharmacist. Online Continuing Education Program, November 1, 2019.

Kennedy ML, Khorassani F. Eating disorders: anorexia nervosa, bulimia nervosa, and binge eating disorders. PharmacotherapyFirst: a multimedia learning resource. Nov 2019.

Khorassani F, Hassani B, Ramchandani D. CPNP 2019 Annual Meeting Poster Abstracts. Evaluation of doctor of pharmacy students in their first through fourth professional years. Ment Health Clin [Internet]. 2019;9(3):156-7.

Khorassani F, Saad M. Intravenous olanzapine for the management of agitation: review of the literature. Ann Pharmacother 2019; 53 (8); 853-59.

Luther K, Fung GM, Khorassani F. Cost comparison of atypical antipsychotics: paliperidone ER and risperidone. Hospital Pharmacy 2018; 54 (6): 389-92.

Khorassani F, Kaufman M, Lopez LV. Supratherapeutic serum clozapine concentration after transition from traditional to electronic cigarettes. J Clin Psychopharmacol 2018 Aug;38(4):391-392.

Khorassani F, Tellier S, Tsapepas D. Pharmacist's role in improving medication adherence in transplant recipients with comorbid psychiatric disorders. J Pharm Pract 2018;32 (5): 568-78.

Luther K, Khorassani F. Movie Review: Requiem for a dream. CPNP Perspectives 2017;4:19.

Khorassani F, Kaufman M, Lopez L. College of Psychiatric and Neurologic Pharmacists 2017 Poster Abstracts. Supratherapeutic serum clozapine concentration after transition from traditional to electronic cigarettes. J Pharm Pract 2017; 30(4) NP17-NP90.

Shirazian S, Grant CD, Aina O, Mattana J, Khorassani F. Ricardo A. Depression in chronic kidney disease and end stage renal disease: similarities and differences in diagnosis, epidemiology, and management. Kidney Int Rep 2017;2:94-107.

Khorassani F, Ahmed M, Su M. College of Psychiatric and Neurologic Pharmacists 2016 Poster Abstracts. Comparison of rehospitalization rates after receiving paliperidone palmitate versus long-acting injectable risperidone in patients with schizophrenia. J Pharm Pract 2016; 29(3) 270-341.

Khorassani F, Misher A, Garris S. The past and present of anti-obesity agents: a focus on monoamine modulators. Am J Health Syst Pharm 2015;72:697-706.

Hillman A, Khorassani F. Symptomatic and disease modifying treatment options for multiple sclerosis. Pharmacy Times 2014;3(2):7-9.

Martin C, Fischer M, Khorassani F. Movie Review: Drugstore Cowboy. Ment Health Clin 2013;3(6):100.

Khorassani F, Hilas O. Bapineuzumab: a novel investigational agent for alzheimer’s disease. P&T 2013;38(2):1-3.

Grant #: 1H79TI026020-01 (completed) Agency/Organization: Substance Abuse and Mental Health Services Administration (SAMHSA) Amount Awarded: $944,138 Award Period: September 2015 - September 2018 Project Title: St. John’s University Screening, Brief Intervention and Referral to Treatment (SBIRT) Student Training Roles: Education and Training Consultant, Faculty Healthcare Partner, Residency Coordinator- PGY2 Academia and Community Health

PGY-1 Residency
NewYork-Presbyterian Hospital- Cornell & Columbia University 2011—2012

PGY-2 Psychiatric Specialty Residency
University of North Carolina Hospitals and Clinics 2012—2013

Link to this profile
https://faculty.uci.edu/profile/?facultyId=7116

Last updated
12/08/2022